IFN-beta-1a vs Mifamurtide
Head-to-head comparison of IFN-beta-1a (Recombinant human interferon beta-1a) and Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | IFN-beta-1a | Mifamurtide |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Recombinant human interferon beta-1a | Muramyl Tripeptide Phosphatidylethanolamine |
| Molecular Weight | ~22,500 Da | N/A |
| Half-Life | 10-19 hours | 2-4 h |
| Amino Acids | 166 | N/A |
| Typical Dose | 30-44 mcg per dose | 2 mg/m2 |
| Route | Intramuscular/Subcutaneous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 1200 | 150 |
| Research Status | Clinical | Clinical |
IFN-beta-1a Benefits
- ✓antiviral gene induction
- ✓innate immune modulation
- ✓reduced viral replication
- ✓well-characterized safety profile
Mifamurtide Benefits
- ✓macrophage-activation
- ✓innate-immune-signaling
- ✓immune-adjuvant-research
- ✓cytokine-response
IFN-beta-1a Dosing
30 mcg intramuscular weekly or 44 mcg subcutaneous three times weekly|Titrate by indication and tolerability|Monitor liver enzymes, blood counts, and injection reactions
Mifamurtide Dosing
2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens
IFN-beta-1a Side Effects
- ⚠flu-like symptoms
- ⚠injection-site reactions
- ⚠liver enzyme elevation
Mifamurtide Side Effects
- ⚠fever/chills
- ⚠fatigue
- ⚠nausea
Research Overview
IFN-beta-1a
Widely studied recombinant interferon beta preparation with a strong evidence base in immune modulation and antiviral biology. Its clinical use demonstrates predictable pharmacology and class-typical interferon effects.
Mifamurtide
Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.